Huperzine A: study protocols
7 study groups say how much Huperzine A participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
623 products in our catalogue print how much Huperzine A a serving holds.
Most common: 50 mcg to 100 mcg, 25% of 623 products.
| Dose per serving | Products |
|---|---|
| 5 mcg or less | 5 |
| 5 mcg to 10 mcg | 89 |
| 10 mcg to 25 mcg | 38 |
| 25 mcg to 50 mcg | 105 |
| 50 mcg to 100 mcg | 157 |
| 100 mcg to 250 mcg | 155 |
| 250 mcg to 500 mcg | 31 |
| 500 mcg to 1 mg | 1 |
| 1 mg to 2.5 mg | 2 |
| 2.5 mg to 5 mg | 16 |
| over 5 mg | 24 |
Dose per serving from research
7 study groups in 5 studies say how much Huperzine A participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 50 mcg to 100 mcg, 43% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mcg to 100 mcg | 3 |
| 100 mcg to 250 mcg | 1 |
| 250 mcg to 500 mcg | 2 |
| 500 mcg to 1 mg | 1 |
Commonly used together
None of these 7 study groups took Huperzine A with anything else.
7 study groups
| Study | |||
|---|---|---|---|
| Treatment with Huperzine A improves cognition in vascular dementia patients 2012 · Huperzine A · Patients with mild to moderate vascular dementia; age and sex not reported | 200 mcg | 12 weeks | 39 |
| [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial] 2002 · huperzine Alpha group · Adults with mild to moderate possible or probable Alzheimer disease; age and sex not reported | 400 mcg | 12 weeks | 100 |
| A phase II trial of huperzine A in mild to moderate Alzheimer disease 2011 · huperzine A 200 μg BID · Adults with mild to moderate Alzheimer disease | 400 mcg | 16 weeks | 70 |
| Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students 1999 · Hup group · Junior middle school students of unspecified age and sex, complaining of memory inadequacy | 100 mcg | 4 weeks | 34 |
| Huperzine-A in capsules and tablets for treating patients with Alzheimer disease 1999 · capsule group · Patients with Alzheimer disease | 100 mcg | 60 days | 30 |
| Huperzine-A in capsules and tablets for treating patients with Alzheimer disease 1999 · tablet group · Patients with Alzheimer disease | 100 mcg | 60 days | 30 |
| A phase II trial of huperzine A in mild to moderate Alzheimer disease 2011 · huperzine A 400 μg BID · Adults with mild to moderate Alzheimer disease | 800 mcg | 16 weeks | 70 |